MetaVia MTVA

NASDAQ MTVA

$1.66 -0.01 (-0.60%)

At close: Sep 29, 2026 · 4:00 PM EDT

Key Stats

Market Cap10.98 Mn

P/E-0.68

Add ratio to table…

About

MetaVia Inc. is a clinical-stage biotechnology company dedicated to developing novel pharmaceuticals targeting cardiometabolic diseases, with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The company operates in the highly specialized biopharmaceutical industry, where it advances therapeutic candidates through rigorous preclinical and clinical development stages. MetaVia’s pipeline is anchored by two lead programs, vanoglipel…

MetaVia Inc. currently generates no commercial revenue, as its business model centers on the research, development, and eventual commercialization of investigational drugs. The company’s revenue potential hinges on successfully navigating regulatory approval processes, securing partnerships, and out-licensing its therapeutic candidates. Future income streams may include milestone payments from licensing agreements, royalties on net sales of approved products, and direct product sales upon market authorization. The company’s financial sustainability depends on its ability to attract funding through capital markets, collaborations, or strategic transactions to support ongoing clinical trials and operational expenses.

The company operates through the following segments:

Cardiometabolic Therapeutics: This segment encompasses the development of vanoglipel (DA-1241) and DA-1726, MetaVia’s two lead drug candidates. Vanoglipel (DA-1241) is a novel GPR119 agonist designed for the treatment of MASH and type 2 diabetes mellitus (T2DM), with potential as both a standalone and combination therapy. DA-1726 is a dual agonist of the GLP-1 and glucagon receptors, targeting obesity through mechanisms that suppress appetite and increase energy expenditure. Both programs are in active clinical trials, with vanoglipel in Phase 2a and DA-1726 in Phase 1, reflecting the segment’s focus on advancing innovative treatments for high-burden metabolic diseases.
Legacy and Out-Licensed Programs: This segment includes four therapeutic candidates—ANA001, NB-01, NB-02, and gemcabene—that are no longer under active development by MetaVia. The company explores out-licensing and divestiture opportunities for these assets, which span indications such as COVID-19, painful diabetic neuropathy, cognitive impairment, and dyslipidemia. While these programs are not a priority for internal advancement, they represent residual value and potential future revenue through partnerships or asset sales.

MetaVia Inc. competes in a dynamic and highly competitive biopharmaceutical landscape, where established players and emerging biotech firms vie for dominance in the cardiometabolic disease market. The company’s primary competitors include pharmaceutical giants such as Novo Nordisk and Eli Lilly, which have commercialized leading obesity and diabetes treatments like semaglutide (Wegovy) and tirzepatide (Zepbound). In the MASH space, MetaVia faces competition from Madrigal Pharmaceuticals, Akero Therapeutics, and 89Bio, among others, all of which are advancing therapies targeting liver fibrosis and metabolic dysfunction. MetaVia’s competitive edge lies in its differentiated mechanisms of action, such as the dual agonism of DA-1726 and the GPR119 pathway modulation of vanoglipel, which may offer improved efficacy or safety profiles compared to existing treatments. The company’s strategic focus on combination therapies and its robust intellectual property portfolio further strengthen its position in a market where innovation and clinical differentiation are critical to success.

MetaVia Inc. serves a broad and evolving customer base within the healthcare ecosystem, primarily targeting patients suffering from MASH, obesity, and related metabolic disorders. The company’s therapeutic candidates are designed for individuals with chronic conditions that lack effective treatment options, positioning MetaVia to address significant gaps in patient care. While the filing does not specify end customers by name, the company’s future commercial efforts will likely engage healthcare providers, including hepatologists, endocrinologists, and primary care physicians, as well as payors such as insurance companies and government health programs. Additionally, MetaVia’s licensing agreements with partners like Dong-A ST and MThera Pharma indicate its engagement with pharmaceutical companies that may further develop or commercialize its assets, expanding its reach across global markets.

Investment Thesis

▲ Bull case

MetaVia's DA-1726 demonstrates a compelling differentiated profile as a dual GLP-1/glucagon receptor agonist, achieving a mean 9.1% body weight reduction at Day 54 in the non-titrated 48 mg cohort without evidence of plateau, suggesting durable efficacy beyond the 8-week period and positioning it favorably against semaglutide which often plateaus earlier, with the mechanism enabling weight loss through both reduced appetite and increased energy expenditure, a dual-action advantage not fully captured in current market expectations for obesity therapies.
Exploratory FibroScan data from the 48 mg cohort showed meaningful liver-related improvements including a −20.0 dB/m reduction in CAP, −10.3% change in liver stiffness via VCTE, and directional improvements in FAST score at Day 54, indicating direct hepatoprotective effects that could support expansion into MASH indications where current GLP-1 agonists lack robust liver fibrosis data, creating a potential dual-indication opportunity that management is actively pursuing through EASL presentations and ongoing studies.
The ongoing Phase 1 Part 3a/3b titration studies evaluating one-step (16 mg to 48 mg) and two-step (16 mg to 32 mg to 64 mg) regimens are designed to optimize tolerability at higher exposures, with management emphasizing this could represent a meaningful advantage over existing therapies requiring longer, more gradual titration, and if successful, may enable faster dose escalation to therapeutic levels while maintaining safety, a de-risking factor not fully priced in given the recent IRB approval and first patient dosing in April 2026 with data expected in Q4 FY26.
MetaVia's strengthened balance sheet shows $13.7 million in cash and cash equivalents as of March 31, 2026, bolstered by the $9.3 million gross proceeds from the January 2026 public offering, which management states is sufficient to fund operations into Q4 FY26, covering the anticipated data readout from Part 3 of the Phase 1 trial and reducing near-term financing risk, a critical factor for a clinical-stage biotech often overlooked in favor of pipeline-only assessments.
The company's intellectual property estate comprises 39 granted and pending patents exclusively licensed from Dong-A ST Co. Ltd., providing protection for DA-1726 through at least 2041, safeguarding its novel peptide structure and long-acting dual-incretin design, which supports long-term commercialization potential and reduces the risk of competitive erosion, a structural advantage in the crowded obesity therapeutics market that is underappreciated in current valuations.

MetaVia's DA-1726 demonstrates a compelling differentiated profile as a dual GLP-1/glucagon receptor agonist, achieving a mean 9.1% body weight reduction at Day 54 in the non-titrated 48 mg cohort without evidence of plateau, suggesting durable efficacy beyond the 8-week period and positioning it favorably against semaglutide which often plateaus earlier, with the mechanism enabling weight loss through both reduced appetite and increased energy expenditure, a dual-action advantage not fully captured in current market expectations for obesity therapies.
Exploratory FibroScan data from the 48 mg cohort showed meaningful liver-related improvements including a −20.0 dB/m reduction in CAP, −10.3% change in liver stiffness via VCTE, and directional improvements in FAST score at Day 54, indicating direct hepatoprotective effects that could support expansion into MASH indications where current GLP-1 agonists lack robust liver fibrosis data, creating a potential dual-indication opportunity that management is actively pursuing through EASL presentations and ongoing studies.
The ongoing Phase 1 Part 3a/3b titration studies evaluating one-step (16 mg to 48 mg) and two-step (16 mg to 32 mg to 64 mg) regimens are designed to optimize tolerability at higher exposures, with management emphasizing this could represent a meaningful advantage over existing therapies requiring longer, more gradual titration, and if successful, may enable faster dose escalation to therapeutic levels while maintaining safety, a de-risking factor not fully priced in given the recent IRB approval and first patient dosing in April 2026 with data expected in Q4 FY26.
MetaVia's strengthened balance sheet shows $13.7 million in cash and cash equivalents as of March 31, 2026, bolstered by the $9.3 million gross proceeds from the January 2026 public offering, which management states is sufficient to fund operations into Q4 FY26, covering the anticipated data readout from Part 3 of the Phase 1 trial and reducing near-term financing risk, a critical factor for a clinical-stage biotech often overlooked in favor of pipeline-only assessments.
The company's intellectual property estate comprises 39 granted and pending patents exclusively licensed from Dong-A ST Co. Ltd., providing protection for DA-1726 through at least 2041, safeguarding its novel peptide structure and long-acting dual-incretin design, which supports long-term commercialization potential and reduces the risk of competitive erosion, a structural advantage in the crowded obesity therapeutics market that is underappreciated in current valuations.

▼ Bear case

Despite positive early data, MetaVia remains a clinical-stage biotechnology with no approved products and significant historical net losses, including a $12.9 million net loss in FY25 and $3.8 million in Q1 FY26, raising concerns about its ability to transition from promising Phase 1 data to costly Phase 2/3 trials, especially given the high failure rate in obesity therapeutics where efficacy in early studies often does not translate to later-stage success due to unanticipated safety signals or insufficient durability.
The company's reliance on a single license agreement with Dong-A ST Co. Ltd. for both DA-1726 and vanoglipel creates concentration risk, as any disruption in this partnership—whether due to financial, regulatory, or strategic disagreements—could severely impair MetaVia's ability to develop, manufacture, or commercialize its lead assets, a vulnerability highlighted in forward-looking statements but not adequately mitigated by diversification efforts given the minimal progress disclosed on vanoglipel beyond Phase 2a data.
While management highlights favorable tolerability in the absence of titration for DA-1726, the ongoing Part 3 studies are explicitly designed to evaluate dose-escalation strategies to "optimize tolerability at higher exposures," implying that higher doses like 64 mg may still present tolerability challenges not yet fully characterized, and the lack of detailed safety data beyond mild-to-moderate GI events in early cohorts leaves open the risk of dose-limiting adverse effects as exposure increases.
The cash runway, while improved, remains constrained, with $13.7 million in cash as of March 31, 2026, and an accumulated deficit of $152.7 million, meaning that even with the January 2026 proceeds, MetaVia will likely require additional financing before or shortly after the Q4 FY26 data readout to advance DA-1726 into Phase 2, potentially leading to dilution or unfavorable financing terms if clinical results are perceived as insufficiently differentiated from competitors like tirzepatide or survodutide.
The market may be overestimating the clinical significance of exploratory liver biomarkers such as FibroScan CAP and FAST scores, which are not yet validated as surrogate endpoints for regulatory approval in MASH, and without histopathological confirmation from biopsy—considered the gold standard—the observed improvements in liver stiffness and fat may not reliably predict long-term clinical benefit, posing a risk that the hepatic signal, while encouraging, does not yet substantiate a viable path to MASH indication approval.

Despite positive early data, MetaVia remains a clinical-stage biotechnology with no approved products and significant historical net losses, including a $12.9 million net loss in FY25 and $3.8 million in Q1 FY26, raising concerns about its ability to transition from promising Phase 1 data to costly Phase 2/3 trials, especially given the high failure rate in obesity therapeutics where efficacy in early studies often does not translate to later-stage success due to unanticipated safety signals or insufficient durability.
The company's reliance on a single license agreement with Dong-A ST Co. Ltd. for both DA-1726 and vanoglipel creates concentration risk, as any disruption in this partnership—whether due to financial, regulatory, or strategic disagreements—could severely impair MetaVia's ability to develop, manufacture, or commercialize its lead assets, a vulnerability highlighted in forward-looking statements but not adequately mitigated by diversification efforts given the minimal progress disclosed on vanoglipel beyond Phase 2a data.
While management highlights favorable tolerability in the absence of titration for DA-1726, the ongoing Part 3 studies are explicitly designed to evaluate dose-escalation strategies to "optimize tolerability at higher exposures," implying that higher doses like 64 mg may still present tolerability challenges not yet fully characterized, and the lack of detailed safety data beyond mild-to-moderate GI events in early cohorts leaves open the risk of dose-limiting adverse effects as exposure increases.
The cash runway, while improved, remains constrained, with $13.7 million in cash as of March 31, 2026, and an accumulated deficit of $152.7 million, meaning that even with the January 2026 proceeds, MetaVia will likely require additional financing before or shortly after the Q4 FY26 data readout to advance DA-1726 into Phase 2, potentially leading to dilution or unfavorable financing terms if clinical results are perceived as insufficiently differentiated from competitors like tirzepatide or survodutide.
The market may be overestimating the clinical significance of exploratory liver biomarkers such as FibroScan CAP and FAST scores, which are not yet validated as surrogate endpoints for regulatory approval in MASH, and without histopathological confirmation from biopsy—considered the gold standard—the observed improvements in liver stiffness and fat may not reliably predict long-term clinical benefit, posing a risk that the hepatic signal, while encouraging, does not yet substantiate a viable path to MASH indication approval.

Peer group

Peer Comparison

Companies in the Biotechnology

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	655.56 Bn	31.13	6.69	49.04 Bn
2	ABBV	AbbVie Inc.	470.94 Bn	74.71	7.31	70.82 Bn
3	MRK	Merck & Co., Inc.	367.14 Bn	115.84	5.52	53.91 Bn
4	NVS	Novartis Ag	280.33 Bn	22.35	5.35	37.49 Bn
5	AZN	Astrazeneca Plc	257.78 Bn	23.71	4.20	-0.11 Bn
6	AMGN	Amgen Inc	226.04 Bn	25.83	5.93	57.30 Bn
7	GILD	Gilead Sciences, Inc.	188.89 Bn	-58.39	6.20	26.25 Bn
8	MTVA	MetaVia Inc.	0.01 Bn	-0.68	-	-

MetaVia MTVA

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password